|
|
|
11-50 employees
View all
|
|
Pharmaceuticals
|
|
Glenwood Ave, Menlo Park, Kalifornien 94025, US
|
|
Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (CelerisTx One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices.
CelerisTx's drug pipeline is focused on CNS and oncology, targeting unmet medical needs. We also co-develop therapeutics with pharmaceutical and biotech companies.
CelerisTx has so far attracted a total of EUR 18 million in committed capital from venture capital funds, which include EIC Fund, Pace Ventures Enigma, i&i biotech, Apex Ventures, R42 and longevitytech.fund.
#targetedproteindegradation #degrader #ubiquitinproteasomesystem #machinelearning #CelerisOne #proximityinducingcompounds #PICs
|
Celeris Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Celeris Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Celeris Therapeutics customer service number call here 00436605586512. To contact Celeris Therapeutics customer service number in your country click here to find.
Christopher Trummer is the CEO of Celeris Therapeutics. To contact Christopher Trummer email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.